PF-04455242

Investigational drug

PF-04455242
Chemical nomenclature
IUPAC name	1-(4-fluorophenyl)-3-((4-((2-methylpyrimidin-4-yl)oxy)piperidin-1-yl)methyl)urea
Identifiers
CAS Number	956905-27-4
PubChem	16005106
ChemSpider	13180813
UNII	0F3X4Q3XUS
KEGG	D09992
ChEMBL	2103874
Chemical data
Chemical formula	C18H23N4O1F1
SMILES	CC1=NC=NC(=C1)OC2CCN(CC2)CNC(=O)NC3=CC=C(C=C3)F
InChI	1S/C18H23FN4O2/c1-13-21-9-10-22-18(13)25-16-7-5-15(6-8-16)23-11-14(24)20-17-3-2-4-19-12-17/h2-4,5-10,12,14H,11H2,1H3,(H,20,24)
InChIKey	ZQKZQXJZQXJZQX-UHFFFAOYSA-N

PF-04455242 is an investigational drug that was developed by Pfizer for the treatment of cognitive disorders such as schizophrenia and Alzheimer's disease. It acts as a selective dopamine receptor D1 antagonist.

Pharmacology

PF-04455242 is designed to target the dopamine receptor D1, which is implicated in various neurological disorders. By antagonizing this receptor, PF-04455242 aims to modulate the dopaminergic system, potentially improving cognitive function in patients with disorders like schizophrenia and Alzheimer's disease.

Mechanism of Action

The drug functions by selectively binding to the D1 subtype of dopamine receptors, inhibiting their activity. This action is thought to help in balancing the dopaminergic activity in the brain, which is often disrupted in cognitive disorders. The modulation of D1 receptors is believed to enhance working memory and executive function, which are typically impaired in these conditions.

Development and Research

Chemical structure of PF-04455242

PF-04455242 has undergone various stages of clinical trials to assess its efficacy and safety. Initial studies focused on its potential benefits in improving cognitive deficits associated with schizophrenia. However, the development of PF-04455242 has faced challenges, including the complexity of targeting specific dopamine receptors without affecting others, which can lead to side effects.

Potential Applications

The primary focus of PF-04455242 is on cognitive enhancement in disorders like schizophrenia and Alzheimer's disease. By improving cognitive functions, the drug could potentially enhance the quality of life for patients suffering from these debilitating conditions. However, further research is needed to fully understand its efficacy and safety profile.

Challenges and Considerations

Developing drugs that target the dopaminergic system is challenging due to the intricate balance required to avoid side effects. The specificity of PF-04455242 for the D1 receptor is crucial in minimizing unwanted interactions with other dopamine receptors, which could lead to adverse effects.

Related pages

• Dopamine receptor D1
• Schizophrenia
• Alzheimer's disease
• Cognitive disorders